This is as of May 11, 2010 -- and it is a $3.8 billion per year hole. New Merck is now admitting, in graphics, no less, that it has no follow-on candidate in the Hypertension space, and Cozaar/Hyzaar is falling like a rock, now that it is available in generic form from Teva [click to enlarge]:
Tuesday, May 11, 2010
New Merck R And D Day 2010 -- One Troubling Slide
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment